A new way to
guide patient care

Definitive answers to guide
better treatment

When it comes to Alzheimer’s disease, early detection is essential to better care. Mayo Clinic Laboratories has developed an innovative evaluation for Alzheimer's disease, which uses CSF biomarkers to achieve a high concordance with amyloid positron emission tomography (PET) scan. This new test also delivers faster results and provides new hope for correctly diagnosing and managing Alzheimer's disease along with other dementias.

Answers for
patients and providers

Diagnosing Alzheimer’s disease is a challenge. We use the most up-to-date methodology: an automated immunoassay with innovative instrumentation. Our results are based on a ratio of p-tau and AB42, which allows for greater than 90% diagnostic accuracy compared to standard assessments. We also use low-binding tubes, resulting in fewer false results for patients.

Clear results that guide treatment decisions

A diagnosis of Alzheimer’s disease can change patients' lives. Receiving a fast, definitive answer from a health care institution they trust can provide hope and a plan for their future. Whether it is the right treatment for symptom management, confirmation of diagnosis, or eligibility for clinical trials, we are here to provide the highest quality of care. 

Fast, cost-effective answers when you need them most

A differential diagnosis can change treatment and improve patient care. With our testing, a patients receive the answers they need in as little as one day. They don’t have to wait weeks or months to be placed on the right treatment and start planning for their future.

A complementary solution to assist
with diagnosis

Standard assessment of suspected Alzheimer's disease patients through clinical and cognitive assessment is 70%-80% accurate. By adding our Alzheimer's disease evaluation, physicians can increase diagnostic accuracy by 12%-22% to ensure they are providing the correct diagnosis and treatment for patients.

Which test should I order?

Confirm neuronal damage

For patients suspected of having Alzheimer’s disease, testing for neurofilament light chains (NFLC), a generic marker of neurodegeneration,  can confirm a neurodegenerative disease process. Mayo Clinic Laboratories has developed an innovative assay to test for elevated levels of NFLC in the blood. Positive test results not only confirm neuronal damage but can offer insights on disease progression and prognosis to guide therapeutic decision-making.

A Test in Focus

Alicia Algeciras-Schimnich, Ph.D., gives an overview of this test. She discusses when this testing should be ordered, how this testing compares to previous testing approaches, and what clinical action can be taken due to the results of this testing.

Learn more about how to order this evaluation at your institution.

Additional resources

Interactive webinar:
The role of CSF in Alzheimer's disease

Cerebrospinal fluid (CSF) has been used in research on Alzheimer’s disease for decades, but only recently have the platforms been developed to standardize measurements across laboratories.

The benefits of using a unique, low-binding tube

We require a specific polypropylene low-binding tube. In clinical studies, this tube has been most effective in preventing Ab42 adsorption and can provide more accurate results for patients. 

Amyloid βeta Confirmed™ Program

Mayo Clinic Laboratories is proud to offer Alzheimer's disease biomarker testing as part of the Biogen sponsored Amyloid βeta Confirmed™ Program. Participating providers will gain access to Mayo Clinic Laboratories' advanced cerebrospinal fluid (CSF) evaluation at no cost* to help broaden access and improve care planning for patients being evaluated for mild cognitive impairment (MCI) or mild dementia clinical stages of Alzheimer's disease.